Nuvasive Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Nuvasive Inc (NUVA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Nuvasive Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,226M vs 197,589M combined for its competitors (0.6% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+3.7% annualized vs trailing 12 months), vs decelerating (-10.2%) for its tracked peer group.
- Growth: Nuvasive Inc generated 2.4% revenue growth year over year in Q2 2023, vs 7.8% for its competitors combined.
- Profitability: Its 2.3% net margin compares with 16.0% for the peer group.
- Peer revenue share: Nuvasive Inc accounted for 0.7% of combined revenue among its tracked peer group, down from 0.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.41M compares with $0.51M for the peer group (0.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NUVA Sales vs. its Competitors, Q2 2023
Nuvasive Inc reported revenue growth of 2.36 % year on year in Q2 2023, below its competitors' combined revenue growth of 7.79 %.
With a net margin of 2.32 %, Nuvasive Inc reported lower profitability than its competitors (16.03 %).
Nuvasive Inc generated 0.71 % of the combined sales of its peer group, down from 0.75 % a year earlier.
API endpoints for this dataset
Nuvasive Inc vs. its Competitors, Q2 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Nuvasive Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Nuvasive Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Nuvasive Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (16) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Nuvasive Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.4% year over year, combined, vs 2.4% for Nuvasive Inc. Nuvasive Inc's share of combined industry revenue moved from 0.30% to 0.27%, a loss of 0.03 percentage points.
Nuvasive Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Nuvasive Inc | Yes | Yes | No | No |
| Competitors combined (41) | ||||
| High-Confidence Competitors (16) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 0.00 % (0 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NUVA Stock Performance relative to its Competitors
NUVA Stock Performance relative to High-Confidence Competitors
NUVA Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Pulse Biosciences Inc | 282.9% | Outperformed |
| 2 | Pro dex Inc | 282.9% | Outperformed |
| 3 | Monogram technologies inc | 282.9% | Outperformed |
| 4 | Orthopediatrics Corp | 282.9% | Outperformed |
| 5 | Adagio Medical Holdings inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Nuvasive Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Nuvasive Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Nuvasive Inc |
2,103.05 | 1,226.23 |
 Johnson and Johnson |
687,517.91 | 99,335.00 |
 Medtronic Plc |
130,553.31 | 37,542.00 |
 Stryker Corp |
124,754.36 | 26,300.00 |
 Edwards Lifesciences Corporation |
60,076.18 | 6,512.50 |
 Zimmer Biomet Holdings Inc |
20,691.30 | 8,508.80 |
| SUBTOTAL | 1,072,837.16 | 198,899.82 |
Sign in to see all competitors of Nuvasive Inc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Nuvasive Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Nuvasive Inc's Competitors Named by the Company
Competitive relationships identified from Nuvasive Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Si bone inc | Company report | 85% |
| Bioventus Inc | Company report | 85% |
| Stryker Corp | Company report | 85% |
| Medtronic Plc | Company report | 85% |
| Alphatec Holdings Inc | Company report | 85% |
| Orthofix Medical Inc | Company report | 85% |
| Smith and Nephew Plc | Company report | 85% |
| Zimmer Biomet Holdings Inc | Company report | 85% |
| Xtant Medical Holdings Inc | Company report | 85% |
| Bone Biologics Corporation | Company report | 85% |
| Boston Scientific | Company report | 85% |
| DePuy Synthes | Company report | 85% |
| ZimVie | Company report | 85% |
| Integra LifeSciences | Company report | 85% |
| VB Spine | Company report | 85% |
| Neuroone Medical Technologies Corp | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Saluda | Company report | 85% |
| Biotronik | Company report | 85% |
| PainTeq | Company report | 85% |
| Elutia Inc | Company report | 85% |
| Stimwave | Company report | 85% |
| Neuspera Medical Inc. | Company report | 85% |
| Nalu Medical, Inc. | Company report | 85% |
| Conformis inc | Company report | 85% |
| Enovis Corp | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Monogram technologies inc | Company report | 85% |
| Surgalign Holdings Inc | Company report | 85% |
| Inspire Medical Systems inc | Company report | 85% |
| Paragon 28 inc | Company report | 85% |
| Tenon Medical Inc | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
| Teleflex Incorporated | Company report | 85% |
| Orthopediatrics Corp | Company report | 85% |
| Vicarious Surgical Inc | Company report | 85% |
| Sintx Technologies Inc | Company report | 85% |
| Prolung Inc | Company report | 85% |
| Neurometrix Inc | Company report | 85% |
| Conmed Corporation | Company report | 85% |
| Utah Medical Products Inc | Company report | 85% |
| Axonics Inc | Company report | 85% |
| Procept Biorobotics Corporation | Company report | 85% |
| Pro dex Inc | Company report | 85% |
| Tactile Systems Technology Inc | Company report | 85% |
| Encision Inc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Cervomed Inc | Company report | 85% |
| Apyx Medical Corp | Company report | 85% |
| Fuse Medical Inc | Company report | 85% |
| Adagio Medical Holdings inc | Company report | 85% |
| Neuropace Inc | Company report | 85% |
| Medinotec Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Nuvasive Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Nuvasive Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Johnson and Johnson | Oncology 29.93 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 56.20 % |
| Edwards Lifesciences Corporation | United States 58.74 % |
| Zimmer Biomet Holdings Inc | Americas Segment 63.91 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Nuvasive Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Nuvasive Inc | 2,103 | 408,742 | 9,483 |
| Johnson and Johnson | 687,518 | 705,504 | 114,311 |
| Medtronic Plc | 130,553 | 395,179 | 55,463 |
| Stryker Corp | 124,754 | 469,643 | 64,696 |
| Edwards Lifesciences Corporation | 60,076 | 407,031 | 62,725 |
| Zimmer Biomet Holdings Inc | 20,691 | 500,518 | 47,476 |
| PEERS TOTAL | 1,070,734 | 512,857 | 69,024 |
Nuvasive Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Nuvasive Inc | United States 75.71 % |
| Johnson and Johnson | United States 58.90 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.92 % |
| Zimmer Biomet Holdings Inc | US 58.44 % |
| Globus Medical Inc | United States 81.31 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Nuvasive Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 71.66 % | 46.20 % (avg) | +25.5 pp |
| Operating Margin | 5.59 % | industry median | +24.5 pp |
| EBITDA Margin | 17.70 % | -6.66 % (avg) | +24.4 pp |
| Capital Intensity (Capex / Revenue) | 11.65 % | 7.13 % (avg) | +4.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Nuvasive Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 82.1x | 36.9x | +45.2x |
| EV / EBITDA | 12.6x | 17.8x | -5.2x |
| P/B | 2.5x | 4.6x | -2.1x |
| Return on Equity | 3.28 % | industry aggregate | 0.64 % |
| Return on Invested Capital | 3.15 % | -6.78 % (avg) | 9.93 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Nuvasive Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 6.39 % | 18.61 % | 7.01 % | 7.01 % | 6.02 % | -10.06 % | 8.41 % | 5.53 % |
| Operating Margin | 17.15 % | 12.84 % | 11.01 % | 4.92 % | 10.53 % | 3.65 % | -1.06 % | 7.36 % |
| Return on Invested Capital | 7.46 % | 6.00 % | 5.27 % | 2.37 % | - | - | -0.43 % | 3.80 % |
| P/E | 40.1x | 98.8x | 36.6x | 245.1x | 61.2x | - | - | 57.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Nuvasive Inc's Strategic Group Map
Nuvasive Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Nuvasive Inc's trailing-12-month revenue growth of 4.4% and operating margin of 5.6% compares with an average of 3.9% growth and 6.4% margin across its 8 closest peers by combined growth, margin and ROIC -- Nuvasive Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Nuvasive Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 11.65 % vs industry average 7.13 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Nuvasive Inc's dedicated Suppliers and Customers pages, not here.
Nuvasive Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Nuvasive Inc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Nuvasive Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 24.5 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+3.7% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-10.2% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Nuvasive Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Nuvasive Inc | 0.28 | 1.21 | 0.87 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.50 | 2.08 | 0.65 |
| Edwards Lifesciences Corporation | 1.74 | 4.14 | 0.06 |
| Zimmer Biomet Holdings Inc | 0.25 | 1.93 | 0.60 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Nuvasive Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Nuvasive Inc | Q2 2023 | +2.4 % | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q3 2026 | +7.6 % | -12.3 % |
| Edwards Lifesciences Corporation | Q2 2026 | +13.7 % | -27.2 % |
| Zimmer Biomet Holdings Inc | Q2 2026 | +4.8 % | +30.1 % |
| PEERS TOTAL | +6.7 % | -41.6 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Nuvasive Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Nuvasive Inc | Q2 2023 | +4.3 % | +4.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q3 2026 | +3.0 % | +26.7 % |
| Edwards Lifesciences Corporation | Q2 2026 | +14.1 % | +35.7 % |
| Zimmer Biomet Holdings Inc | Q2 2026 | +7.3 % | +45.3 % |
Nuvasive Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Nuvasive Inc | 1.31% | 2.17% | 3.28% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.66% | 8.63% | 15.61% |
| Edwards Lifesciences Corporation | 7.41% | 8.39% | 9.65% |
| Zimmer Biomet Holdings Inc | 3.51% | 3.97% | 6.36% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Nuvasive Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Nuvasive Inc | 79.50 | 1.72 |
| Johnson and Johnson | 42.48 | 6.92 |
| Medtronic Plc | 298.79 | 3.48 |
| Stryker Corp | 34.54 | 4.74 |
| Edwards Lifesciences Corporation | 59.88 | 9.22 |
| Zimmer Biomet Holdings Inc | 26.05 | 2.43 |
| PEERS AVERAGE | 40.28 | 5.39 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.